June 24, 2025

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: CuraTeQ Biologics receives approval for biosimilar Dyrupeg from UK's MHRA – Reg.,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that –

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version. Earlier in April 2025, Dyrupeg™ received marketing authorization in the European Union from the European Commission (EC). This is CuraTeQ's third biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by BADDIGAM ADI REDDY
Date: 2025.06.24 16:47:52 +05'30'
B. Adi Reddy
Company Secretary